Successful Pain Management for the Postherpetic Neuralgia of Ophthalmic Nerve by Continuous Subcutaneous Infusion of Ketamine: A case report

1997 ◽  
Vol 33 (4) ◽  
pp. 774 ◽  
Author(s):  
Hoi Sang Yang ◽  
Kyeong Ho Lee ◽  
Cheol Lee ◽  
Won Tae Kim
1996 ◽  
Vol 82 (4) ◽  
pp. 413-415 ◽  
Author(s):  
Carla Ripamonti ◽  
Chiara Ticozzi ◽  
Ernesto Zecca ◽  
Carlos H. Rodriguez ◽  
Franco De Conno

Ketorolac is a new non-steroidal anti-inflammatory drug (NSAID) having a potent nonopioid analgesic activity. Administered by continuous subcutaneous infusion (CSI), its analgesic efficacy has been documented in the treatment of somatic and visceral cancer pain whilst it has been shown to be ineffective in the treatment of neuropathic pain. Here is a description of a cancer patient with neuropathic pain unresponsive to anticonvulsant or antidepressant drugs administered in association or not with oral opioids but who was successfully treated with ketorolac alone via CSI. Furthermore, the analgesia lasted over 75 days of treatment without any significant renal and gastric side effects.


2007 ◽  
Vol 20 (2) ◽  
pp. 190 ◽  
Author(s):  
Jeong Hun Suh ◽  
Mi Suk Koo ◽  
Francis Sahngun Nahm ◽  
Hwa Yong Shin ◽  
Yong Min Choi ◽  
...  

2005 ◽  
Vol 19 (3) ◽  
pp. 199-203 ◽  
Author(s):  
Tomoyuki Kawamata ◽  
Yasumitsu Sato ◽  
Yukitoshi Niiyama ◽  
Keiichi Omote ◽  
Akiyoshi Namiki

Cosmetics ◽  
2022 ◽  
Vol 9 (1) ◽  
pp. 10
Author(s):  
Kamal Alhallak ◽  
Adel Abdulhafid ◽  
Salem Tomi ◽  
Dima Omran

Hypodermoclysis is the continuous subcutaneous infusion of a parenteral solution into dermal tissue, which is typically associated with skin lesions and cosmetic issues in the majority of patients. Scarring and pigmentation are two of the potential skin lesions after hypodermoclysis. The way skin diseases and cosmetic issues are treated has altered dramatically as a result of laser technology. This is the first article to our knowledge that describes the treatment of pigmentation and scarring produced by Hypodermoclysis cutaneous damage by using laser treatment. It was vital to select the appropriate endpoint, technology, and configuration parameters. The lesion was completely resolved after five months of treatment with four laser sessions. The first session used a fractional Er-Yag laser to perform cold ablation. The remaining sessions used 1064 and 585 nm Nd-Yag Q-switch lasers to operate in the nanosecond region. To minimize the danger of post-inflammatory hyperpigmentation (PIH), the treated region was prepped between laser treatments with 4% hydroquinone (HQ) cream. Our protocol may reduce scars and pigmentation while minimizing adverse effects and downtime.


1982 ◽  
Vol 47 (01) ◽  
pp. 001-002 ◽  
Author(s):  
Nenita Parrilla ◽  
Jack Ansell

SummaryA preliminary clinical trial was conducted to determine the feasibility of achieving and regulating therapeutic anticoagulation with heparin given by continuous subcutaneous infusion. Five patients with deep venous thrombosis confirmed by impedance plethysmography and/or venography were studied. All patients received an initial heparin dose of 5000 units by IV bolus. This was followed by a continuous subcutaneous heparin infusion at a dose of 15 to 25 units per kilogram per hour. Effective levels of anticoagulation were achieved in all five patients. Regulation and maintenance of therapeutic anticoagulation were no more difficult than with intravenous therapy. No major complications were encountered during therapy.Continuous subcutaneous infusion of heparin may have advantages over standard intravenous therapy or high dose intermittent subcutaneous therapy. However, more extensive clinical evaluation is warranted.


2004 ◽  
Vol 17 (2) ◽  
pp. 275
Author(s):  
Ju Yeon Choi ◽  
Yun Jin Kim ◽  
Hee Jung Baik ◽  
Jong Hak Kim

2004 ◽  
Vol 17 (2) ◽  
pp. 255
Author(s):  
Soo Bong Yu ◽  
Sang Wook Shin ◽  
Seung Hun Baek ◽  
Chul Hong Kim ◽  
Kyung Hoon Kim ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document